Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
October 10 2022 - 07:37AM
GlobeNewswire Inc.
Houston, Texas
and Tuebingen,
Germany, October
10, 2022 – Immatics N.V. (NASDAQ:
IMTX, “Immatics”), a clinical-stage biopharmaceutical company
active in the discovery and development of T cell-redirecting
cancer immunotherapies, announced today that it has agreed to sell,
by way of an underwritten public offering, 10,905,000 of its
ordinary shares at a price of $10.09 per share. The gross proceeds
from the offering, before deducting the underwriting discount and
offering expenses, are expected to be approximately $110 million.
The offering is expected to close on October 12, 2022, subject to
customary closing conditions.
The offering included participation from investors including
Armistice Capital Master Fund Ltd., Dellora Investments, EcoR1
Capital, Nantahala Capital, Perceptive Advisors, Rock Springs
Capital, RTW Investments, LP, Samsara BioCapital, SilverArc
Capital, Sofinnova Investments, Wellington Management, 683 Capital
and other specialist biotech investors.
Jefferies and SVB Securities are acting as joint book-running
managers for the offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission (the “SEC”)
and was declared effective on August 9, 2021. The offering is being
made only by means of a prospectus supplement and accompanying
prospectus. When available, copies of the final prospectus
supplement and accompanying prospectus related to the offering may
be obtained for free from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, telephone: (877) 821-7388, email:
Prospectus_Department@Jefferies.com; or SVB Securities LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email:
syndicate@svbsecurities.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act of 1933, as amended.
- END -
About
ImmaticsImmatics combines the discovery of true
targets for cancer immunotherapies with the development of the
right T cell receptors with the goal of enabling a robust and
specific T cell response against these targets. This deep know-how
is the foundation for our pipeline of Adoptive Cell Therapies and
TCR Bispecifics as well as our partnerships with global leaders in
the pharmaceutical industry. We are committed to delivering the
power of T cells and to unlocking new avenues for patients in their
fight against cancer.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
closing of the public offering and gross proceeds therefrom are
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “may”, “should”,
“expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Immatics and its
management, are inherently uncertain. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to, various factors beyond management's control including
general economic conditions and other risks, uncertainties and
factors set forth in filings with the SEC. Nothing in this press
release should be regarded as a representation by any person that
the forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Immatics undertakes no duty to update these
forward-looking statements.
For more information, please
contact:
Media and Investor Relations
Contact |
Jacob Verghese or Eva Mulder |
|
Trophic Communications |
|
Phone: +49 89 2070 89831 or +31 65 2331 579 |
|
immatics@trophic.eu |
|
Immatics N.V. |
|
Anja Heuer |
Jordan Silverstein |
Director, Corporate Communications |
Head of Strategy |
Phone: +49 89 540415-606 |
Phone: +1 281 810 7545 |
media@immatics.com |
InvestorRelations@immatics.com |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2023 to Jun 2023
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Jun 2022 to Jun 2023